{{Rsnum
|rsid=10264784
|Chromosome=7
|position=19869907
|Orientation=plus
|GMAF=0.2663
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Summary=Associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.17, combined P value= 3.79E-04.
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 23.2 | 76.8
| HCB | 13.3 | 57.0 | 29.6
| JPT | 21.2 | 52.2 | 26.5
| YRI | 17.7 | 50.3 | 32.0
| ASW | 17.5 | 38.6 | 43.9
| CHB | 13.3 | 57.0 | 29.6
| CHD | 9.2 | 45.9 | 45.0
| GIH | 7.9 | 33.7 | 58.4
| LWK | 12.7 | 45.5 | 41.8
| MEX | 5.2 | 34.5 | 60.3
| MKK | 6.4 | 39.7 | 53.8
| TSI | 0.0 | 20.6 | 79.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10264784
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.17, combined P value= 3.79E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470238
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10264784
|overall_frequency_n=35
|overall_frequency_d=128
|overall_frequency=0.273438
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}